Clinical trials
Relapse clinical trials
Below are recruiting relapse clinical trials, each written for real people, not researchers. We’re tracking 892 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07250087RecruitingPhase 1
Asciminib maintenance after transplant or CAR T for Ph+ALL
This trial tests a pill called asciminib given after a stem cell transplant or CAR T therapy to help prevent relapse in adults with Philadelphia chromosome-positive ALL. It is for people whose cancer is currently in remission.
Tampa, FloridaAges 18 years+ - NCT07256210RecruitingPhase 2
Donor NK cells to prevent leukemia return after stem cell transplant
This trial tests whether giving donor natural killer (NK) cells after a stem cell transplant can help prevent leukemia from coming back. It is for people aged 14-25 with certain hard-to-treat leukemias who are already getting a stem cell transplant from a related donor.
MoscowAges 1 month–25 years - NCT07257419RecruitingPhase 1
CAR T cells and stem cell transplant for leukemia and lymphoma
This trial tests giving special immune cells (CAR T cells) after a half-matched stem cell transplant. It's for children and young adults with high-risk leukemia or lymphoma that has come back or not responded to treatment.
Memphis, TennesseeAges Up to 21 years - NCT07248176Recruiting
Universal CAR-T therapy for multiple myeloma
This trial tests a universal CAR-T cell therapy (made from donated cells) for multiple myeloma that has come back after at least two prior treatments. It may be an option if your cancer cells have a specific marker called BCMA and you have not had certain prior therapies.
ShanghaiAges 18 years+ - NCT07242963Recruiting
Study of Shh medulloblastoma with U1 mutation
This study looks at people with a certain type of brain tumor called sonic hedgehog medulloblastoma that has come back or not responded to treatment. Researchers want to learn more about these tumors that have a specific genetic change (U1 mutation), which may help find better treatments in the future.
Houston, TexasAges 3–50 - NCT07249073RecruitingEarly Phase 1
Dual-target CAR-T for relapsed/refractory myeloma
This trial tests a new CAR-T cell therapy that targets two proteins (BCMA and CD19) on myeloma cells. It may help patients whose myeloma has come back or stopped responding to previous treatments.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07237230Recruiting
Gamma-delta T cells to prevent leukemia relapse after transplant
This trial tests if a special type of immune cell called gamma-delta T cells can help prevent acute myeloid leukemia from coming back after a stem cell transplant. It is for people with high-risk features who have recently had a transplant.
Wuhan, HubeiAges 18–65 - NCT07225985RecruitingPhase 1/Phase 2
Pralatrexate, bendamustine, and radiation before donor stem cell transplant for T-cell lymphoma
This trial tests a combination of two chemotherapy drugs (pralatrexate and bendamustine) plus total-body radiation before a donor stem cell transplant for people with T-cell lymphoma that has come back or hasn't responded to treatment. The goal is to see if this approach can help destroy the lymphoma and allow the donor cells to take hold safely.
Seattle, WashingtonAges 18 years+ - NCT07230015Recruiting
Imagery and balance training for MS
This study tests if combining mental practice of movements with balance exercises helps people with relapsing-remitting MS who have mild balance problems and dizziness. It aims to improve stability and reduce vertigo.
Istanbul, Beykoz/İstanbulAges 18–45 - NCT07222618Recruiting
Selfie videos to measure function in MS
This trial asks people with MS to record short 'selfie' videos of themselves doing everyday tasks, like walking or getting dressed. The goal is to find a better, more personal way to measure how MS affects daily function.
San Francisco, CaliforniaAges 18 years+ - NCT07227311RecruitingPhase 2
Belantamab mafodotin combinations for relapsed multiple myeloma
This trial tests a new drug called belantamab mafodotin (a targeted antibody therapy) combined with standard treatments for multiple myeloma that has come back or stopped responding. It looks at three different drug combinations to see which works best for people who have had 1 or 2 prior treatments.
Los Alamitos, CaliforniaAges 18 years+ - NCT07223840RecruitingPhase 2
A study of brenipatide to help former smokers stay smoke-free
This trial tests an injectable drug called brenipatide to see if it helps people who have recently quit smoking stay quit for good. The study follows participants over time and requires them to come to clinic visits.
Rogers, ArkansasAges 18–75 - NCT07227818RecruitingPhase 3
Testing NBI-1117568 to prevent schizophrenia relapse
This trial tests a new medicine, NBI-1117568, to see if it can help prevent a relapse of schizophrenia symptoms. It is for adults who have been stable on other antipsychotics and want to avoid returning to the hospital for a psychiatric stay.
Garden Grove, CaliforniaAges 18–65 - NCT07222761RecruitingPhase 3
Comparing new treatments for relapsed multiple myeloma
This trial tests if a new medicine called linvoseltamab, alone or combined with carfilzomib, works better than the usual treatments for people with multiple myeloma that has come back or stopped responding after 1 to 3 prior therapies.
Atlanta, GeorgiaAges 18 years+ - NCT06911710RecruitingPhase 1/Phase 2
Car-T therapy for relapsed blood cancers
This trial tests whether CAR-T cells, a type of immunotherapy that targets specific markers on cancer cells, can treat blood cancers that have come back or not responded to standard treatment. It may offer a new option for people with lymphoma, leukemia, or multiple myeloma.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06914037RecruitingPhase 1
CHT101 for CD70-positive blood cancers
This trial tests a new drug, CHT101, for people with certain blood cancers that have not responded to prior treatments. It is specifically for cancers that test positive for a protein called CD70.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT06918912RecruitingPhase 2
Loncastuximab tesirine for lymphoma after CAR-T therapy
This trial tests a drug called loncastuximab tesirine for people with diffuse large B-cell lymphoma or high-grade B-cell lymphoma that has come back or not responded after CAR-T cell therapy. It aims to see if the drug can help when other treatments have stopped working.
Alessandria, ALESSANDRIAAges 18–99 - NCT03936153RecruitingPhase 2
Oral abexinostat for relapsed lymphoma after two prior treatments
This Phase 2 study tests how well and how safely an oral medicine called abexinostat works for people with diffuse large B-cell lymphoma that has come back or did not respond to the last treatment. It may help by shrinking lymphoma and controlling the disease using a medication taken by mouth.
BeijingAges 18 years+ - NCT04775485RecruitingPhase 2
Targeted medicine for children with certain brain or solid tumors
This Phase 2 study tests tovorafenib, a targeted cancer medicine, in children and young adults whose tumors have specific BRAF or RAF changes. It is for cancers that have come back or grown despite previous treatment, with measurable signs on scans.
San Francisco, CaliforniaAges 6 months–25 years - NCT06118788RecruitingPhase 1/Phase 2
BG1805 for relapsed or refractory acute myeloid leukemia
This trial tests a new treatment, BG1805, for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. It targets a specific marker on leukemia cells called CLL-1.
Guangzhou, GuangdongAges 18–70 - NCT05956457Recruiting
Using wearable and PRO check-ins for relapsed myeloma
This study uses your self-reported symptoms (PRO) and wearable/device data to help improve care for people with relapsed multiple myeloma who are starting new treatment. It may help by providing insights about how you’re doing during therapy—without changing your cancer treatment in a study-specific way.
Seattle, WashingtonAges 18 years+ - NCT07197580RecruitingPhase 3
Study of a targeted radiation therapy for advanced kidney cancer
This trial tests a new drug called 177Lu-TLX250, which delivers radiation directly to kidney cancer cells. It is for people with advanced clear cell renal cell carcinoma that has returned or not responded to at least 2 prior treatments.
Sydney, New South WalesAges 18 years+ - NCT07193823Recruiting
Sexual function study for women with MS
This study looks at sexual health in women with relapsing-remitting multiple sclerosis. It aims to understand how MS might affect sexual function and to find ways to help.
Izmir, BornovaAges 25–50 - NCT07198867RecruitingPhase 1
A-CAR028 for relapsed or refractory AML
This trial tests a new cell therapy called A-CAR028 for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The therapy uses your own immune cells to fight the cancer.
Hangzhou, ZhejiangAges 18–75
Hear when a new Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapse?
- Yes. Clin2 currently lists 892 recruiting relapse studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapse trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapse trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.